PANNEX Therapeutics is developing Pannexin 1 channel blockers to enhance immune response and inhibit tumor growth in triple-negative breast cancer and other aggressive cancers. This targeted therapy aims to improve treatment efficacy while minimizing metastasis and associated side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Triple-negative breast cancer and other aggressive cancers often exhibit poor clinical outcomes due to limited treatment options and a propensity for metastasis. Current therapies may not effectively target the multiple pathways that drive tumor growth and immune evasion, leading to disease progression and reduced patient survival.
Solution
PANNEX Therapeutics is developing a novel class of cancer drugs that function as Pannexin 1 channel (Panx1) blockers. By blocking Panx1 channels, the therapy aims to enhance the immune system's response to tumors, curb tumor growth, and minimize the spread of metastases. This targeted approach disrupts disease-related pathways, potentially leading to safer and more effective treatments for life-threatening cancers and severe neurological diseases. The modulation of Panx1 channels represents a new strategy to improve disease progression and outcomes in cancers where this channel is overexpressed.
Target Audience
The primary target audience includes patients with triple-negative breast cancer and other aggressive cancers, as well as individuals suffering from severe neurological diseases where Pannexin 1 channels play a significant role.
Features
- First-in-class Pannexin 1 channel (Panx1) blockers
- Targeted therapy designed to enhance the immune system's response to tumors
- Mechanism of action focuses on disrupting disease-related pathways by blocking Panx1 channels
- Potential application in treating triple-negative breast cancer (TNBC) and other aggressive cancers
- May also be applicable to severe neurological diseases like chronic pain